Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 7/20 | 0.43 |
| ▸ | CCNC | P24863 | 6/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.38 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.36 |
| ▸ | TCF7 | P36402 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958837 | 1.00 | CDK8 (0.43) | CDK8CCNCMKNK2ATMCDC7 | |
| SCHEMBL256345 | 0.83 | CCNC (0.40) | CDK8CCNCATMCDC7TRPM5 | |
| SCHEMBL31298637 | 0.74 | HDAC8 (0.37) | MKNK2ATMCDC7HASPINHDAC8 | |
| SCHEMBL31298606 | 0.74 | HDAC8 (0.40) | MKNK2ATMCDC7HASPINHDAC8 | |
| SCHEMBL12775602 | 0.74 | CYP17A1 (0.41) | MKNK2ATMCDC7HASPINHDAC8 | |
| SCHEMBL16339750 | 0.74 | HDAC8 (0.47) | MKNK2ATMCDC7HASPINHDAC8 | |
| SCHEMBL19258536 | 0.74 | HASPIN (0.53) | MKNK2HASPINRPS6KA5HDAC8NPC1 | |
| SCHEMBL25952935 | 0.74 | SLC6A2 (0.41) | MKNK2ATMCDC7HASPINHDAC8 | |
| SCHEMBL47226 | 0.73 | CYP1A2 (0.47) | CDK8TRPA1NPC1TP53MAPT | |
| SCHEMBL29487677 | 0.73 | CYP1A2 (0.47) | CDK8TRPA1NPC1TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | AGIOS PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | ORYZON GENOMICS, S.A. (ES) | 2023-01-26 | — | — | US | disclosed |
| WO-2022263548-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | LEAD DISCOVERY CENTER GMBH (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4104901-A1 | 3-SUBSTITUTED 1H-PYRROLO[2,3-B]PYRIDINE AS GRK5 MODULATORS | Lead Discovery Center GmbH (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | AGIOS PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| CN-115215886-A | Compounds and compositions as endosomal Toll-like receptor inhibitors | 诺华股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022187693-A1 | COVALENT CDK2-BINDING COMPOUNDS FOR THERAPEUTIC PURPOSES | UMBRA THERAPEUTICS INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-09 | — | — | US | disclosed |
| WO-2011116951-A1 | PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2011-09-29 | — | — | WO | disclosed |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
| US-7807684-B2 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7767687-B2 | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors | BIOGEN IDEC MA INC. (US) | 2010-08-03 | — | — | US | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11872225-B2 | Pyruvate kinase modulators and use thereof | PDK1, PDK2, PDK4 | CDK8 545/4885CCNC 2590/4885MKNK2 124/4885 |
| US-20230203048-A1 | SPIROPYRROLIDINE DERIVED ANTIVIRAL AGENTS | ACE, ACE2, PKD1 | CDK8 3595/4885CCNC 1450/4885MKNK2 2965/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | CDK8 179/4885CCNC 2797/4885MKNK2 3803/4885 |
| US-20220395503-A1 | PYRUVATE KINASE ACTIVATORS FOR USE IN TREATING BLOOD DISORDERS | PDK1, PDK2, PDK3 | CDK8 374/4885CCNC 2751/4885MKNK2 244/4885 |
| US-20120035370-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CDK8 657/4885CCNC 2496/4885MKNK2 2733/4885 |
| US-20230026909-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE 6 INHIBITORS | HDAC6, HDAC1, HDAC3 | CDK8 732/4885CCNC 2598/4885MKNK2 777/4885 |
| US-20110059976-A1 | PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | CDK8 46/4885CCNC 395/4885MKNK2 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.